Clinical Trials Logo

Clinical Trial Summary

In this study the application of cold atmospheric plasma (CAP) will be tested on intact skin of volunteers. To test safety, several skin parameters will be monitored, the antimicrobial effect will be investigated as well. The investigators expect this treatment to have a good antimicrobial effect with acceptable, transient skin sensations.

Clinical Trial Description

Control of infection and bacterial colonisation constitutes a continuing challenge in patients with burns. Prevention of microbial contamination and infection is vital for burn wound care as bacterial presence can result in excessive inflammatory reactions, delayed re-epithelialisation, impaired matrix remodelling and bacteraemia. A novel method to decrease the likelihood of infection and to help cure wounds is cold atmospheric plasma (CAP). CAP has been shown in vitro to kill a wide range of pathogenic bacteria.

This safety study aims to demonstrate the safety, efficacy and efficiency of CAP for burn wound treatment. Intact skin of volunteers will be CAP treated. Local skin reaction (blister formation, pain, itching), erythema, local skin temperature, trans epidermal water loss (TEWL) and reduction of the bacterial load wil be monitored. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03007264
Study type Interventional
Source Association of Dutch Burn Centres
Status Completed
Phase Phase 1
Start date June 18, 2018
Completion date July 26, 2018

See also
  Status Clinical Trial Phase
Completed NCT04192123 - Open-Label Test of the HM242 Medical Devices to Evaluate Safety and Local Tolerability N/A